HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods
Top Cited Papers
Open Access
- 28 April 2004
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 291 (16) , 1972-1977
- https://doi.org/10.1001/jama.291.16.1972
Abstract
The human epidermal growth factor receptor 2, HER-2 (HER-2/neu or c-erbB-2), oncoprotein is overexpressed in 20% to 25% of invasive breast cancers.1 Previous studies have supported the importance of HER-2 overexpression as an independent prognostic marker of clinical outcome,1-5 as a predictor of benefit from doxorubicin-based chemotherapy,6,7 and for metastatic disease, for benefit from the anti–HER-2 antibody, trastuzumab.8-11 Determination of HER-2 status is now an integral part of the clinical-pathological workup of breast cancer.Keywords
This publication has 26 references indexed in Scilit:
- Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast CarcinomaLaboratory Investigation, 2000
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999
- Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast CancerJournal of Clinical Oncology, 1999
- erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast CancerJNCI Journal of the National Cancer Institute, 1998
- HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.Journal of Clinical Oncology, 1997
- Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.Journal of Clinical Oncology, 1990
- HER-2/neu oncogene protein and prognosis in breast cancer.Journal of Clinical Oncology, 1989
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989